1 (edited by PCL1029 Sun, 07 Apr 2013 07:11:52)

Topic: My Take on The 3rd CanLiv Hepatobiliary Research symposium on 4/5/2013

Hi,everyone,
Kim, Barbara and me attended the 3rd annual CanLiv research symposium at DC on April5. The topic is " Harnessing Genomics-Driven Therapy for Hepatobiliary Cancers".
Below is the summary of what I have learned from the meeting.
I asked Dr. Gores from Mayo Clinics about his opinion on what if the only FDA approved targeted agent Sorafenib ( a multiple pathways TKI) won't work anymore and what other targeted agent will he recommend next. He said it looks like mTOR pathway agents will be the next choice. He also acknowledged that it is too expensive to search and develop single pathway TKI and preferred if it can, develop multiple pathway TKIs.
From him, I also learned that subsets of patients can been benefited from Sorafenib and other TKIs that even though the research article is negative about the drug as a whole for the patient population in the study. This is also concur by another researcher in the meeting.
I asked Dr.jack Wands,of the Brown university/Rhode Island Hospital liver research center who specialized in hepatocellular carcinoma genomics research as well as on immunotherapy , He indicated that as a patient, I should look into both the immunotherapy and using the genomics-driven therapy to maximize my chance of survival. The immunotherapy such as adoptive cell therapy and vaccines research have come a long way but has gained ground recently in cancer research. He also agreed very much with Dr Gores about the findings that the future potential benefit of the Notch genes in cancer research and development.
I asked Dr. Daniel Catenacci ,he is currently the principle investigator for 14 clinical trials from University of Chicago ,about his opinion maintenance chemotherapy since he had mentioned it casually on one of his published research article. He indicated he does not have any opinion on it since not a lot of research had been done on that subject, but he thinks it may be of benefit to some patient. He is very friendly to talk to and has shown great interest in individuals like me who is relatively beat the odds and still survive ; he will be a great researcher and clinician for years to come.
I ask Dr. Kiguchi from University of Texas at Austin,about the comparison between DCA and DCM, the suspected chemical agent that caused cholangiocarcinoma in a printing company in Japan recently; one is dichloro -acetic acid(DCA) and the other one is dichloromethane(DCM), what I am trying to do is to find out whether these two compounds are related since  both carried carbon and 2 chloride atoms,[DCA=C2H2cl2O2  and DCM=CH2cl2] And they both can be used as caustic agents ; he said he did not know the answer.
To be continued.
God bless

Please know that my personal opinion is not intended nor implied to be a substitute for professional medical advice. If  provided, information are for educational purposes.Consult doctor is a MUST for changing of treatment plans.

Re: My Take on The 3rd CanLiv Hepatobiliary Research symposium on 4/5/2013

Percy, thank you very much for posting this summary for us.

You have my full attention with DCA. I will look into it.

Re: My Take on The 3rd CanLiv Hepatobiliary Research symposium on 4/5/2013

Many thanks for this Percy. And to Kim and Barbara as well! Great stuff and thanks so much to you all for attending the symposium in DC!!

Gavin

Any advice or comments I give are based on personal experiences and knowledge and are my opinions only, they are not to be substituted for professional medical advice. Please seek professional advice from a qualified doctor or medical professional.

Re: My Take on The 3rd CanLiv Hepatobiliary Research symposium on 4/5/2013

Percy,
Thank you
Hugs
Lisa

This Information Is Not Intended Nor Implied To Be A Substitute For Professional Medical Advice. You Should Always Seek The Advice Of Your Physician Or Other Qualified Health Care Provider

Re: My Take on The 3rd CanLiv Hepatobiliary Research symposium on 4/5/2013

Great information!  I was pleased that you had a positive impression of Dr. Catenacci.  My husband wasn't eligible for his clinical trial but we were quite impressed by his knowledge and ease with patients and anticipate more interaction with him in the future.